COVID-19 Resource Center / Treatments & Research / COVID-19 Outpatient Therapeutics
COVID-19 Outpatient Therapeutics
Statement regarding Omicron Subvariants
11/21/22 Update: The CDC has reported a rapid increase in the circulation of certain COVID-19 variants in the US that are known to be ineffective to several monoclonal antibody (mAb) therapies for the prevention and treatment of COVID-19. Stanford Health Care has been monitoring these variants of concern within our geographic region and has decided we will no longer offer:
- Evusheld for pre-exposure prophylaxis (effective 11/23/22)
- Bebtelovimab for treatment (effective 11/21/22)
At this time, we highly encourage you to stay updated with the latest COVID-19 boosters and take necessary precautions (e.g. masking in public indoor areas) to avoid exposure.
If you develop COVID-19, please inform your healthcare provider and fill out the SHC treatment self-referral form below. There are several therapeutics that remain active against these resistant subvariants and could be considered treatment options (Paxlovid, remdesivir, or molnupiravir). A member of the COVID Outpatient Therapeutics team will contact you to discuss options for COVID-19 treatment. Thank you for understanding.
Thank you,
The SHC COVID-19 Outpatient Therapeutics Team
General Information for Patients
Stanford Health Care is offering COVID-19 therapeutics for treatment or prevention in eligible patients, whether within or outside of the Stanford Health Care system, in accordance with national guidelines.
Due to the evolving variants and supply of medications, Stanford Health Care will select the specific therapeutic based individual patient factors.
To learn more about currently recommended therapeutics, please visit https://www.covid19treatmentguidelines.nih.gov/ or talk to your doctor.
Request to be screened for treatment:
For pre-exposure prophylaxis, talk to your provider to initiate a referral.
General Information for Patients
Stanford Health Care is offering COVID-19 therapeutics in the outpatient setting for treatment in eligible patients, whether within or outside of the Stanford Health Care system, in accordance with national guidelines.
Stanford Health Care will select the specific therapeutic based on clinical efficacy, susceptibility to circulating COVID-19 variants, individual patient factors, medication availability, and administration feasibility.
To learn more about currently recommended therapeutics, please visit https://www.covid19treatmentguidelines.nih.gov/ or talk to your doctor.
Request to be screened for treatment:
Treatment of Mild-Moderate COVID-19
Depending on age, health history, and duration of COVID-19 symptoms, you may qualify for a treatment for the infection.
The most current treatments offered can be found in the patient self-referral form.
Eligibility Requirements
- Test positive for COVID-19
- Be less than 7 days from onset of symptoms
- Meet one or more high-risk criteria include:
High-risk criteria
- Over 65 years old
- Over 55 years old with comorbidities such as cardiovascular disease, high blood pressure, COPD or other chronic respiratory disease
- Over 18 years old with comorbidities such as diabetes, immunosuppressive disease, chronic kidney disease, congenital heart disease, pregnancy, or obesity (elevated BMI)
For the most current information on conditions that may increase risk for severe COVID, please refer to the CDC guidance
Instructions for Appointment
While in the treatment center, you must keep your mask on the entire time and not have anything to eat or drink. Bathroom facilities are available.
If you have questions, please send an email to dl-shc-pharmacy-covid@stanfordhealthcare.org. A member of the Monoclonal Antibody Infusion Center team will respond to your email.
Locations
(additional treatments sites may be available)
Neuro Wellness Infusion Center
213 Quarry Road, 1st Floor
Palo Alto, CA 94304
Are you a health care provider?
Tell your health care provider about all of your medical conditions, including if you:
- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medications (prescription, over-the-counter, vitamins, and herbal products)
- Have any bleeding disorder or are taking medications that increase your risk of bleeding
- Have any heart conditions
- Treatment of COVID-19 is prescribed as an oral treatment or given to you through a vein (intravenous or IV).
- Your health care provider will determine the treatment option.
- You will be monitored by a nurse for one hour after intravenous treatment.
There are several treatments available to treat COVID-19. Currently, treatment options for mild to moderate COVID-19 in non-hospitalized patients include Paxlovid (nirmatrelvir/ritonavir), remdesivir (IV infusion for three consecutive days), and molnupiravir. Your healthcare provider will select the therapy that is available and most effective against the current COVID-19 virus. You will be given more detailed information about the specific medication at the time that you receive therapy.
Other potential treatment options may include high-titer COVID-19 convalescent plasma (CCP).
It is your choice to be treated or not to be treated. Should you decide not to seek treatment or stop it at any time, it will not change your standard medical care.
Tell your health care provider right away if you have any side effect that bothers you or does not go away. Report side effects to FDA MedWatch at fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
Stanford Health Care will bill your insurance for the administration of all COVID services. The out of pocket will depend on insurance plan and benefits.
- Ask your health care provider.
- Visit Health and Human Services.
- Contact your local or state public health department.
- The United States FDA has made some treatments available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services' (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.